Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice

Vaccine

Volumn 34, Issue 5, 2016, Pages 622-629

  Zhang, Jie ^a,b,c   Fan, Hui Ying ^a,b,c   Zhang, Zhen ^a,b,c   Zhang, Juan ^a   Zhang, Jiao ^a,b,c   Huang, Jian Ni ^a   Ye, Yu ^a,b,c   Liao, Ming ^a,b,c  

^a SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

^b AGRO ENVIRONMENTAL PROTECTION INSTITUTE   (China)

^c National and Regional Joint Engineering Laboratory for Medicament of Zoonosis Prevention and Control   (China)

Author keywords

Baculovirus; H5N1; Influenza; LTB; M2e

Indexed keywords

BACULOVIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; INFLUENZA VACCINE; PROTEIN M2; UNCLASSIFIED DRUG; VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; IMMUNOGOLD ELECTRON MICROSCOPY; IN VIVO STUDY; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; T LYMPHOCYTE; VIRUS SHEDDING; ANIMAL; BACULOVIRIDAE; BAGG ALBINO MOUSE; BRONCHOALVEOLAR LAVAGE FLUID; CROSS PROTECTION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; MUCOSAL IMMUNITY; ORTHOMYXOVIRIDAE INFECTIONS; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; BACULOVIRIDAE; BRONCHOALVEOLAR LAVAGE FLUID; CD8-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS; VIRUS SHEDDING;

EID: 84953721135     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.12.039     Document Type: Article

References (45)

1. WHO H5N1 highly pathogenic avian influenza: timeline of major events 2014, WHO, 〈http://www.who.int/influenza/human_animal_interface/h5n1_avian_influenza_update20140714.pdf〉.
2. Watanabe Y., Ibrahim M.S., Suzuki Y., Ikuta K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol 2012, 20:11-20.
3. WHO Evolution of the influenza A (H5) haemagglutinin: WHO/OIE/FAO H5 working group reports a new clade designated 2.3.4.4 2015, WHO, 〈http://www.who.int/influenza/gisrs_laboratory/h5_nomenclature_clade2344/en/〉.
4. Li Q., Wang X., Gu M., et al. Novel H5 clade 2.3.4.6 viruses with both α-2, 3 and α-2, 6 receptor binding properties may pose a pandemic threat. Vet Res 2014, 45:127.
5. Li Q., Wang X., Gao Z., et al. Novel reassortant H5N5 viruses bind to a human-type receptor as a factor in pandemic risk. Vet Microbiol 2015, 175:356-361.
6. WHO WHO China statement on H5N6 2014, WHO, 〈http://www.wpro.who.int/china/mediacentre/releases/2014/20140507/en/〉.
7. Chen H. Avian influenza vaccination: the experience in China. Rev Sci Tech (Int Off Epizoot) 2009, 28:267-274.
8. Subbarao K., Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 2007, 7:267-278.
9. Liao M. Current situation of avian influenza and its influence on the poultry industry. Vet Orientation 2014, 17:11-12. 〈http://www.cnki.com.cn/Article/CJFDTotal-DWBJ201417009.htm〉 In Chinese.
10. Ito T., Gorman O.T., Kawaoka Y., Bean W.J., Webster R.G. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol 1991, 65:5491-5498.
11. Liu W., Zou P., Ding J., Lu Y., Chen Y.H. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 2005, 7:171-177.
12. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988, 62:2762-2772.
13. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990, 64:1375-1377.
14. Deng L., Cho K.J., Fiers W., et al. M2e-based universal influenza A vaccines. Vaccine 2015, 3:105-136.
15. Schotsaert M., Filette M.De, Fiers W., Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009, 8:499-508.
16. Turley C.B., Rupp R.E., Johnson C., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2. 4xM2e) in healthy adults. Vaccine 2011, 29:5145-5152.
17. Ramos E.L., Mitcham J.L., Koller T.D., et al. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J Infect Dis 2015, 211:1038-1044.
18. Newsted D., Fallahi F., Golshani A., Azizi A. Advances and challenges in mucosal adjuvant technology. Vaccine 2015, 33:2399-2405.
19. Verweij W.R., de Haan L., Holtrop M., et al. Musosal immunoadjuvant activity of recombinant Escherichia coli heatlabile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen. Vaccine 1998, 16:2069-2076.
20. Millar D.G., Hirst T.R., Snider D.P. Escherichia coli heat-labile enterotoxin B subunit is a more potent mucosal adjuvant than its closely related homologue, the B subunit of cholera toxin. Infect Immun 2001, 69:3476-3482.
21. Yamanaka H., Ishibashi D., Yamaguchi N., et al. Enhanced mucosal immunogenicity of prion protein following fusion with B subunit of Escherichia coli heat-labile enterotoxin. Vaccine 2006, 24:2815-2823.
22. Sun Z., Lawson S., Langenhorst R., et al. Construction and immunogenicity evaluation of an epitope-based antigen against swine influenza A virus using Escherichia coli heat-labile toxin B subunit as a carrier-adjuvant. Vet Microbiol 2013, 164:229-238.
23. Kost T.A., Condreay J.P., Jarvis D.L. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol 2005, 23:567-575.
24. Chen C.Y., Lin C.Y., Chen G.Y., Hu Y.C. Baculovirus as a gene delivery vector: recent understandings of molecular alterations in transduced cells and latest applications. Biotechnol Adv 2011, 29:618-631.
25. Yin J., Li G., Ren X., Herrler G. Select what you need: a comparative evaluation of the advantages and limitations of frequently used expression systems for foreign genes. J Biotechnol 2007, 127:335-347.
26. Quattrocchi V., Molinari P., Langellotti C., Gnazzo V., Taboga O., Zamorano P. Co-inoculation of baculovirus and FMDV vaccine in mice, elicits very early protection against foot and mouth disease virus without interfering with long lasting immunity. Vaccine 2013, 31:2713-2718.
27. Hervas-Stubbs S., Rueda P., Lopez L., Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. J Immunol 2007, 178:2361-2369.
28. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol 1938, 27:493-497.
29. Zhang J., Chen X.W., Tong T.Z., Ye Y., Liao M., Fan H.Y. BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens. Vaccine 2014, 32:664-670.
30. Guo H., Santiago F., Lambert K., Takimoto T., Topham D.J. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol 2011, 85:448-455.
31. Vries E.de, Guo H., Dai M., Rottier P.J.M., van Kuppeveld F.J.M., de Haan C.A.M. Rapid emergence of highly pathogenic avian influenza subtypes from a subtype H5N1 hemagglutinin variant. Emerg Infect Dis 2015, 21:842-846.
32. Simmons C.P., Mastroeni P., Fowler R., et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J Immunol 1999, 163:6502-6510.
33. Fu N., Khan S., Quinten E., et al. Effective CD8+ T cell priming and tumor protection by enterotoxin B subunit-conjugated peptides targeted to dendritic cells. Vaccine 2009, 27:5252-5258.
34. Da Hora V.P., Conceição F.R., Dellagostin O.A., et al. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011, 29:1538-1544.
35. Abe T., Takahashi H., Hamazaki H., et al. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 2003, 171:1133-1139.
36. Abe T., Hemmi H., Miyamoto H., et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 2005, 79:2847-2858.
37. Neirynck S., Deroo T., Saelens X., et al. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999, 5:1157-1163.
38. Kim M.C., Song J.M., Eunju O., Kwon Y.M., Lee Y.J., Compans R.W., et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 2013, 21:485-492.
39. Wang L., Hess A., Chang T.Z., et al. Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines. Nanomed: Nanotechnol Biol Med 2014, 10:473-482.
40. Thomas P.G., Keating R., Hulse-Post D.J., Doherty P.C. Cell-mediated protection in influenza infection. Emerg Infect Dis 2006, 12:48.
41. Lee Y.N., Lee Y.T., Kim M.C., et al. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology 2014, 143:300-309.
42. Price G.E., Soboleski M.R., Lo C.Y., et al. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 2010, 5:13162.
43. Lukacher A.E., Braciale V.L., Braciale T.J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med 1984, 160:814-826.
44. Kim E.H., Lee J.H., Pascua P.N., et al. Prokaryote-expressed M2e protein improves H9N2 influenza vaccine efficacy and protection against lethal influenza A virus in mice. Virol J 2013, 10:104.
45. Park J.K., Lee D.H., Cho C.H., et al. Supplementation of oil-based inactivated H9N2 vaccine with M2e antigen enhances resistance against heterologous H9N2 avian influenza virus infection. Vet Microbiol 2014, 169:211-217.